

## Conflicts of interests

The Work Under Consideration for Publication					
		<b>Weißhaar, Elke</b>	<b>Garcovich, Simone</b>	<b>Ständer, Sonja</b>	<b>Streit, Markus</b>
1	Grant	None	None	None	None
2	Consulting fee or honorarium	None	None	None	None
3	Support for travel to meetings for the study or other purposes	None	None	None	None
4	Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like	None	None	None	None
5	Payment for writing or reviewing the manuscript	None	None	None	None
6	Provision of writing assistance, medicines, equipment, or administrative support	None	None	None	None
7	Other	None	None	None	None

\* This means money that your institution received for your efforts on this study.

Relevant financial activities outside the submitted work					
1	Board membership	Galderma, Menlo	Celgene, Menlo Therapeutics, Abbvie, Pierre Fabre	Beiersdorf, Celgene, Galderma, Kiniksa, Menlo, NeRRe, Novartis, Sienna, Trevi	yes
2	Consultancy	None	None	Beiersdorf, Celgene, Galderma, Kiniksa, Menlo, NeRRe, Novartis, Sienna, Trevi	None
3	Employment	None	None	None	None
4	Expert testimony	None	None	None	None
5	Grants/grants pending	None	None	None	None
6	Payment for lectures including service on speakers bureaus	Münster Pruritus workshop 6.-	None	None	yes

		8.9.2018			
7	Payment for manuscript preparation	None	None	None	None
8	Patents (planned, pending or issued)	None	None	None	None
9	Royalties	None	None	None	None
10	Payment for development of educational presentations	None	None	None	None
11	Stock/stock options	None	None	None	None
12	Travel/accommodations/meeting expenses unrelated to activities listed**	None	None	None	None
13	Other (err on the side of full disclosure)	Principal Investigator for Menlo and TREVI	None	Investigator for Dermasence, no honorarium	None

\* This means money that your institution received for your efforts.

\*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Other relationships					
1	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	None	None	None	None

The Work Under Consideration for Publication					
		<b>Gieler, Uwe</b>	<b>Misery, Laurent</b>	<b>Şavk, Ekin</b>	<b>Mettang, Thomas</b>
1	Grant	None	None	None	None
2	Consulting fee or honorarium	None	None	None	None
3	Support for travel to meetings for the study or other purposes	None	None	None	None
4	Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like	None	None	None	None
5	Payment for writing or reviewing the manuscript	None	None	None	None
6	Provision of writing assistance, medicines, equipment, or administrative support	None	None	None	None
7	Other	None	None	None	None

\* This means money that your institution received for your efforts on this study.

Relevant financial activities outside the submitted work					
1	Board membership	Galderma (Rosacea) Lilly (Psoriasis) AbbVie (Psoriasis/Hidradenitis supp) Almirall (Adherence)	Bayer Lilly Menlo Novartis Pierre Fabre Sanofi Trevi	None	None
2	Consultancy	None	Amgen Bayer Beiersdorf Celgene Expanscience Lilly Nestlé Pierre Fabre	None	None
3	Employment	Univ. Dept Dermatology University Giessen / Dept. of Dermatology / Hamad Medical Cooperation Doha Qatar	None	None	None
4	Expert testimony	None	None	None	None
5	Grants/grants pending	PsoTrain/grant (AbbVie)	BASF Beiersdorf Celgene	None	None

			Clarins Expanscience Johnson&Johnson Pierre Fabre Uriage		
6	Payment for lectures including service on speakers bureaus	Galderma AbbVie Almirall Bayer Beiersdorf Galderma GSK Janssen Johnson&Johnson Leo Lilly Merz Novartis Pierre Fabre Roche Posay Sanofi Vichy	Abbvie Bioderma Celgene Janssen Leo Novartis Pfizer Pierre Fabre Roche-Posay Sanofi UCB	None	FMC – speakers honorary for Peritoneal dialysis
7	Payment for manuscript preparation	Almirall (Adherence Paper Am J Clin Dermatol) Galderma (Burden of Rosacea, submitted)	Beiersdorf Bioderma Pierre Fabre Sanofi	None	None
8	Patents (planned, pending or issued)	None	None	None	None
9	Royalties	None	None	None	None
10	Payment for development of educational presentations	Atopic dermatitis academy Hessen payed by insurance companies	Abbvie Celgene Intercept	None	None
11	Stock/stock options	None	None	None	None
12	Travel/accommodations/meeting expenses unrelated to activities listed**		Abbvie Janssen Lilly Novartis Pfizer Sanofi	None	None
13	Other (err on the side of full disclosure)		Amgen Biogen Galderma GSK Janssen Leo Lilly Novartis Sanofi Trevi	None	None

\* This means money that your institution received for your efforts.

\*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Other relationships
---------------------

1	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	None	None	None	None
---	---	------	------	------	------

The Work Under Consideration for Publication					
		<b>Wallengren, Joanna</b>	<b>Dalgard, Florence</b>	<b>Gimenez Arnau</b>	<b>Szepietowski, Jacek C.</b>
1	Grant	None	None	BAYER Pruritus management in Contact Dermatitis	None
2	Consulting fee or honorarium	None	None	None	None
3	Support for travel to meetings for the study or other purposes	None	None	None	None
4	Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like	None	None	None	None
5	Payment for writing or reviewing the manuscript	None	None	None	None
6	Provision of writing assistance, medicines, equipment, or administrative support	None	None	None	None
7	Other	None	None	None	None

\* This means money that your institution received for your efforts on this study.

Relevant financial activities outside the submitted work					
1	Board membership	None	None	URIACH, NOVARTIS, GENENTECH, SANOFI	AbbVie, Celgene, Galenica, Leo Pharma, Pierre- Fabre, Novartis, Menlo, Trevi
2	Consultancy	None	None	None	Dignity Sciences, Sanzoz
3	Employment	None	None	None	No
4	Expert testimony	None	None	None	No
5	Grants/grants pending	None	None	URIACH, NOVARTIS, Instituto Carlos III-FEDER	No
6	Payment for lectures including service on speakers bureaus	None	None	URIACH, NOVARTIS, MENARININ, LEO-PHARMA	AbbVie, Galenica Janssen, Leo Pharma, Novartis, SunFarm, Sandoz, Eli Lilly
7	Payment for manuscript preparation	None	None	None	Galenica
8	Patents (planned,	None	None	None	None

	pending or issued)				
9	Royalties	None	None	None	None
10	Payment for development of educational presentations	None	None	URIACH, NOVARTIS, MENARININ	None
11	Stock/stock options	None	None	None	None
12	Travel/accommodations/meeting expenses unrelated to activities listed**	None	None	None	Medac
13	Other (err on the side of full disclosure)	None	None	None	None

\* This means money that your institution received for your efforts.

\*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Other relationships					
1	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	None	None	None	Investigator in Clinical Trials: AbbVie, Actelion, Amgen, GSK, Merck, Novartis, Regeneron, Takeda, Trevi

The Work Under Consideration for Publication					
		<b>Lambert, Julien</b>	<b>Leslie, Tabi</b>	<b>Name</b>	<b>Name</b>
1	Grant	None	None		
2	Consulting fee or honorarium	None	None		
3	Support for travel to meetings for the study or other purposes	None	None		
4	Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like	None	None		
5	Payment for writing or reviewing the manuscript	None	None		
6	Provision of writing assistance, medicines, equipment, or administrative support	None	None		
7	Other	None	None		

\* This means money that your institution received for your efforts on this study.

Relevant financial activities outside the submitted work					
1	Board membership	Novartis, Leo Pharma, Celgene	None		
2	Consultancy	Novartis, Leo Pharma, Celgene	None		
3	Employment	None	None		
4	Expert testimony	None	None		
5	Grants/grants pending	None	None		
6	Payment for lectures including service on speakers bureaus	Novartis, Leo Pharma, Celgene	None		
7	Payment for manuscript preparation	None	None		
8	Patents (planned, pending or issued)	None	None		
9	Royalties	None	None		
10	Payment for development of educational presentations	None	None		
11	Stock/stock options	None	None		
12	Travel/accommodations/meeting expenses unrelated	Novartis, Celgene	None		



	to activities listed**				
13	Other (err on the side of full disclosure)	None	None		

\* This means money that your institution received for your efforts.

\*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Other relationships					
1	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	None	Unpaid advisory: Novartis Menlo		